S
Swee Lay Thein
Researcher at National Institutes of Health
Publications - 335
Citations - 21617
Swee Lay Thein is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Fetal hemoglobin & Population. The author has an hindex of 62, co-authored 316 publications receiving 19670 citations. Previous affiliations of Swee Lay Thein include King's College & University of Oxford.
Papers
More filters
Journal ArticleDOI
Genetic basis of hemolytic anemia caused by pyrimidine 5 ' nucleotidase deficiency
Anthony M. Marinaki,Emilia Escuredo,John A. Duley,H. Anne Simmonds,Adolfo Amici,Valeria Naponelli,Giulio Magni,Martin Seip,Isaac Ben-Bassat,Eric H. Harley,Swee Lay Thein,David C. Rees +11 more
TL;DR: This study is the first description of the structure and location of the P5'N-1 gene, and 3 mutations have been identified in affected patients from separate kindreds.
Journal ArticleDOI
A genetic marker for elevated levels of haemoglobin F in homozygous sickle cell disease
J. S. Wainscoat,Swee Lay Thein,Doug Higgs,John I. Bell,D. J. Weatherall,B. H. Al-Awamy,Graham R. Serjeant +6 more
TL;DR: Ten patients with sickle cell (SS) disease from a Jamaican family were found to have unusually high levels of haemoglobin F for this population, and genetic analysis of the family suggests that there is a determinant linked to the β‐globin gene cluster, characterized by this haplotype, which is responsible for increased haemochemistry F production in response to anaemia.
Journal ArticleDOI
Genetic association studies in β-hemoglobinopathies
TL;DR: In this article, a review summarizes recent genetic studies and key genetic modifiers identified and traces the story of fetal hemoglobin genetics, which has led to an emerging network of globin gene regulation.
Journal ArticleDOI
How I treat renal complications in sickle cell disease
TL;DR: Alongside the invasive treatment regimes, it is important to remember that renal failure in conjunction with sickle cell disease does carry a significant burden of morbidity and that focusing on symptom control has to be central to good patient care.
Journal ArticleDOI
Is it dominantly inherited beta thalassaemia or just a beta-chain variant that is highly unstable?
TL;DR: The purpose of this review is to assess current understanding of the molecular basis for the pathophysiology underlying this subgroup of b thalassaemias in the light of the numerous mutations affecting the b-globin gene and to make a case for the dominantly inherited b thAlassaemic haemoglobinopathies being a phenotypic class of their own.